Drug Trial Radar · NCT03873324
Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Oct 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Dec 20, 2018
Primary completion
Sep 16, 2019
Study completion Sep 16, 2019
Sponsor
- Lead sponsor
- Celon Pharma SAIndustry
- Sponsor type
- Industry
- Collaborators
- National Center for Research and Development, Poland
- First posted
- Mar 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The planned study is to determine the safety and pharmacokinetic properties of CPL500036 compound after single and multiple (two weeks) administration in healthy volunteers.
Conditions
- Healthy Volunteers
Interventions
CPL500036 compoundDrug
IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).
PlaceboDrug
matching placebo capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determination of maximum tolerated dose (MTD) or administration of the maximum dose provided in the protocol after single and multiple oral administration of IMP.Time frame: up to 24 hours after single administration of IMP in PART A and up to 24 hours after the last IMP administration in PART B
- Safety and tolerability of IMP after single and multiple oral administration based on laboratory values, vital signs, ECG, physical examinations and Adverse Events monitoring.Time frame: up to 14 days in PART A and up to 28 days in PART B of the study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
BioResearch Group Sp. z o.o.
Kajetany, Nadarzyn, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.